Lysine deacetylases and regulated glycolysis in macrophages by Shakespear, Melanie R. et al.
Dear author, 
Please note that changes made in the online proofing system will 
be added to the article before publication but are not reflected in 
this PDF. 
We also ask that this file not be used for submitting corrections. 
1 [128_TD$DIFF]Series: Immunometabolism
2 Review
3
Lysine Deacetylases and Regulated
4
Glycolysis in Macrophages
5 [TD$FIRSTNAME] elanie R. [TD$FIRSTNAME.E] [TD$SURNAME] hakespear [TD$SURNAME.E]Q1 ,1 [TD$FIRSTNAME] bishek [TD$FIRSTNAME.E] [TD$SURNAME]Iyer [TD$SURNAME.E],1,2 [TD$FIRSTNAME]Catherine Youting [TD$FIRSTNAME.E] [TD$SURNAME]Cheng [TD$SURNAME.E],3 [TD$FIRSTNAME]Kausta [TD$FIRSTNAME.E] [TD$SURNAME] as Gupta [TD$SURNAME.E],1 [TD$FIRSTNAME] mit [TD$FIRSTNAME.E] [TD$SURNAME] inghal[TD$SURNAME.
E],3,4,5 [TD$FIRSTNAME] avid P. [TD$FIRSTNAME.E] [TD$SURNAME]Fairlie [TD$SURNAME.E],1,2 and [TD$FIRSTNAME] atthew J.[TD$FIRSTNAME.E] [TD$SURNAME] weet [TD$SURNAME.E]1,*
Regulated cellular metabolism has emerged as a fundamental process con-
trolling macrophage functions, but there is still much to uncover about the
precise [105_TD$DIFF]signaling mechanisms involved. Lysine acetylation [141_TD$DIFF]in macrophages
regulates the activity, stability [142_TD$DIFF], and/or localization of metabolic enzymes, as
well as inﬂammatory [143_TD$DIFF]responses. Two protein families, the classical zinc-depen-
dent histone deacetylases (HDACs) and the [144_TD$DIFF]NAD-dependent HDACs (sirtuins,
SIRTs [145_TD$DIFF]), mediate lysine deacetylation. [146_TD$DIFF]We describe here mechanisms by which
classical HDACs and SIRTs directly regulate speciﬁc glycolytic enzymes, as
well as evidence that [147_TD$DIFF]links these protein deacetylases to the regulation of
glycolysis-related genes. In these contexts, we discuss HDACs and SIRTs
as key control points for regulating immunometabolism and inﬂammatory out-
puts from macrophages.
6 Regulated [149_TD$DIFF]Glycolysis in Myeloid Cell-Mediated Inﬂammation and Disease
7 Organismal [150_TD$DIFF][152_TD$DIFF]Q3 survival requires the capacity to combat infection, metabolize nutrients, and store
8 energy for times of need. It is therefore not surprising that metabolism and inﬂammation, two
9 fundamental biological processes that are crucial for sustaining life, are intimately linked.
10 Macrophages are key sentinel cells charged with the task of detecting and responding to
11 homeostatic alterations such as pathogen invasion, metabolic stress, and/or tissue damage.
12 Flexibility in metabolic pathways allows these cells to rapidly respond to changes in their
13 environment. ‘Naïve’ or resting macrophages utilize glycolysis (Box 1) to generate pyruvate,
14 which is [153_TD$DIFF]oxidized into acetyl-CoA for use by the [154_TD$DIFF]tricarboxylic acid (TCA) cycle, feeding electrons
15 in the form of NADH and FADH2 into mitochondrial oxidative phosphorylation (OXPHOS) to
16 generate ATP. However, in response to [123_TD$DIFF]proinﬂammatory stimuli, such as those that activate
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Box 1. The [81_TD$DIFF]Glycolysis Pathway
Glycolysis [82_TD$DIFF][84_TD$DIFF][86_TD$DIFF][88_TD$DIFF]Q12 converts one molecule of glucose into two molecules of pyruvate, two molecules of ATP, and two molecules
of NADH via a series of intermediate metabolites. Flux through this pathway is regulated in multiple ways: availability of
substrate, amount of rate-limiting enzyme present, allosteric regulation by metabolites, and PTMs of the enzymes
involved. Glucose uptake is mediated by cell-surface glucose transporters, and key control points in this pathway are
the irreversible reactions catalyzed by hexokinase, phosphofructokinase, and pyruvate kinase. Hexokinase catalyzes
the ﬁrst step of glucose metabolism, the rate-limiting ATP-dependent phosphorylation of glucose into glucose-6-
phosphate [33]. This phosphorylation event also effectively prevents glucose from exiting the cell and helps commit
glucose-6-phosphate towards energy metabolism pathways such as glycolysis and the pentose phosphate pathway
[33]. Phosphofructokinase [89_TD$DIFF]catalyzes the third glycolytic reaction [90_TD$DIFF]: transfer of a phosphoryl group from ATP to fructose-6-
phosphate, yielding fructose-1, [91_TD$DIFF]6-bisphosphate (F-1, 6-BP). These two enzymatic reactions consume ATP[92_TD$DIFF]; however,
the second half of glycolysis generates [93_TD$DIFF]four molecules of ATP, resulting in the net production of [94_TD$DIFF]two ATP molecules
through this metabolic pathway. Pyruvate kinase, which [89_TD$DIFF]catalyzes the ﬁnal step of glycolysis, converting phosphoe-
nolpyruvate into pyruvate, is activated by the upstreammetabolite F-1, [95_TD$DIFF]6-BP. Inmammalian cells, pyruvate then has two
fates[96_TD$DIFF]: it is either reduced by lactate dehydrogenase to lactate or [97_TD$DIFF]is converted by pyruvate dehydrogenase to acetyl-CoA
for use in the TCA cycle.
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17 Toll-like receptors (TLRs), rapid [155_TD$DIFF]energy and biochemical requirements are met by metabolic
18 reprogramming that [156_TD$DIFF]favors aerobic glycolysis over OXPHOS. This phenomenon, known as the
19 Warburg effect [1], has been well studied in cancer cells and, more recently, in macrophages
20 and other immune cells [2,3].
21 Speciﬁc alterations in levels of metabolites, as well as [157_TD$DIFF]in the functions of metabolic enzymes, are
22 associated with metabolic reprogramming in activated macrophages [4]. For example, TLR
23 [105_TD$DIFF]signaling instructs the cell to increase glucose uptake and convert it to lactate, [158_TD$DIFF]whereasOXPHOS
24 is suppressed [159_TD$DIFF]by disruptions in the electron transport chain [5]. Carbon[160_TD$DIFF]-tracing experiments [6]
25 demonstrate fragmentation at speciﬁc points in the TCA cycle, resulting in a build-up of key
26 metabolitessuchascitrate that canbeused for fatty acid synthesis and/or converted to itaconate,
27 which has both [161_TD$DIFF]antimicrobial [7] and anti-inﬂammatory [8] properties. Succinate accumulates in
28 activatedmacrophages, also as a consequence of TCA cycle disruption, and acts as amolecular
29 switch for [162_TD$DIFF]the initiationof inﬂammatory responses; thismetabolite [163_TD$DIFF]stabilizes the transcription factor
30 HIF-1a, thus enabling inducible expression of [123_TD$DIFF]proinﬂammatory andglycolytic genes [9]. Studies in
31 proliferating cancer cells have been highly informative for understanding howmetabolic enzymes
32 control immunometabolism in immune cells. For example, inmost cells, pyruvate kinaseM (PKM)
33 [89_TD$DIFF]catalyzes the ﬁnal step of glycolysis [164_TD$DIFF]– the conversion of phosphoenolpyruvate to pyruvate.
34 However, in rapidly dividing cells and activated immune cells, an alternatively [165_TD$DIFF]spliced isoform
35 of PKM, PKM2, acts in an [166_TD$DIFF]alternative role as a transcriptional [167_TD$DIFF]coactivator to drive expression of
36 glycolyticand inﬂammatorygenes. In thisway,PKM2playsacentral role indriving theshift towards
37 aerobicglycolysis.Froma therapeuticstandpoint, interferingwith thesemetabolicadaptations, for
38 example by inhibiting glycolytic ﬂux using 2-deoxy-D-glucose [9,10] or by interfering with the
39 transcriptional functions of PKM2 [11,12], reduces macrophage inﬂammatory outputs and
40 inﬂammation-related pathology. Nonetheless, our understanding of the precisemolecular mech-
41 anisms of metabolic control of innate immune processes is still [168_TD$DIFF]rudimentary. Deciphering such
42 mechanisms, together with identifying the key [105_TD$DIFF]signalingmetabolites and regulatory enzymes that
43 control thismetabolic switch,mayunlocknewopportunities to target immunometabolic circuits in
44 immune cells to dampen inﬂammation-associated pathology. Lysine deacetylases are key sus-
45 pects given their well-established roles as cancer- and inﬂammation-associated regulatory
46 enzymes that can also be modulated pharmacologically. Intriguingly, the capacity of metabolic
47 enzymes to be regulated by lysine acetylation seems to be a common mechanism of control
48 (Figure 1, Key Figure), positing this post-translationalmodiﬁcation as a possiblemolecular switch,
49 and an important pharmacological target, for regulating cellular metabolism and inﬂammation.
50 Roles for [169_TD$DIFF]Lysine Deacetylases in Immunometabolism in Macrophages
51 Reversible [170_TD$DIFF]Q4 lysine acetylation is a common post-translational modiﬁcation (PTM) that is now
52 implicated in both immunological and metabolic pathways. This PTM is controlled by histone
53 deacetylases (HDACs, that remove acetyl group from lysine residues) and histone acetyltrans-
54 ferases (HATs, that add acetyl groups to lysine residues). The HDAC family includes the
55 classical zinc-dependent HDACs (classes I, II and IV) and the NAD+[171_TD$DIFF][130_TD$DIFF]-dependent class III HDACs,
56 also known as silent mating-type information regulation 2 (sirtuins or SIRTs). Emerging evi-
57 dence suggests that the classical HDACs and SIRTs modify the activity, stability [142_TD$DIFF], and localiza-
58 tion of some metabolic enzymes to regulate immunometabolism. Furthermore, in carrying out
59 their biochemical functions, HDACs also control the availability of certain intermediary metab-
60 olites. These can play important secondary [105_TD$DIFF]signaling roles, directing the fate and function of a
61 cell in response to external stressors and nutritional cues.
62 Like itaconate and succinate, acetyl-CoA is a metabolite used by cells to link nutrient availability
63 and metabolic status with cellular [105_TD$DIFF]signaling, chromatin structure[172_TD$DIFF], and gene expression.
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Key Figure
Examples of Metabolic Pathways Regulated by Deacetylation
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Figure 1. Examples are provided of how lysine deacetylation regulatesmetabolic enzymes that play key gatekeeping roles
in metabolic pathways. Abbreviations: [3_TD$DIFF]GAPDH, glyceraldehyde-3-phosphate dehydrogenase; [4_TD$DIFF]G6PD, glucose-
6- [5_TD$DIFF]phosphate dehydrogenase; HK, hexokinase; PDH, pyruvate dehydrogenase; 6PGD, 6-phosphogluconate dehydro-
genase; [6_TD$DIFF]PKM2, pyruvate kinase M2; [7_TD$DIFF]SDH, succinate [8_TD$DIFF]dehydrogenase; TCA cycle, tricarboxylic acid cycle.
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64 Numerous metabolic pathways, including glycolysis-derived pyruvate oxidation and b-oxida-
65 tion of fatty acids, generate a mitochondrial pool of acetyl-CoA, which is [173_TD$DIFF]metabolized via the
66 TCA cycle to yield NADH. Distinct cytosolic and nuclear pools of acetyl-CoA can also be
67 created from mitochondrial export or by other enzymatic reactions [13]. Acetyl-CoA in each
68 compartment is used as the donor for HAT-mediated addition of acetyl groups to lysine
69 residues of target proteins. Classical HDACs, which carry out the reverse reaction of lysine
70 deacetylation, generate acetate that can then be converted by acetyl-CoA synthetases to
71 acetyl-CoA [14,15], thus providing an additional means of generating this metabolite. As
72 discussed in this review, deacetylation of lysine residues on rate-limiting metabolic enzymes
73 could also either inhibit or increase enzyme activity to support nutrient ﬂux through a particular
74 pathway. Thus, by regulating both the cellular acetyl-CoA pool and the acetylation status of
75 metabolic enzymes, HATs and HDACs can control cellular metabolism. In keeping with this
76 concept, small[174_TD$DIFF]-molecule inhibitors of classical HDACs alter cellular metabolism [16,17]. For
77 example, HDAC inhibition in myeloma cells resulted in decreased glucose uptake over a 48 [175_TD$DIFF]h
78 period as a result of repression of glucose transporter expression and inhibition of the glycolytic
79 enzyme hexokinase [16]. There is also some evidence to suggest that there is interplay between
80 the metabolic shift and the [123_TD$DIFF]proinﬂammatory functions of speciﬁc HDACs in activated macro-
81 phages [18].
82 [176_TD$DIFF]NAD+ is another metabolite used as a coenzyme in metabolic reactions, as well as a co-
83 substrate for the SIRTs. During glycolysis, NAD+[177_TD$DIFF] is reduced to NADH, and then [178_TD$DIFF]oxidized back to
84 NAD+ during reduction of pyruvate to lactate or during mitochondrial OXPHOS. Cells therefore
85 use the NAD+[179_TD$DIFF]/NADH ratio to monitor metabolic activity and redox state. SIRT[180_TD$DIFF]-mediated
86 deacetylation of target proteins is coupled to the cleavage of NAD+[181_TD$DIFF] to nicotinamide (NAM [145_TD$DIFF]),
87 and theO-acetyl-ADP-ribosemoiety of NAD+[182_TD$DIFF] acts as the acceptor of the acetyl group. Dynamic
88 changes occur in the NAD+[179_TD$DIFF]/NADH ratio during TLR activation of macrophages, and these are
89 sensed by SIRTs to instruct the metabolic shift that supports early[183_TD$DIFF]- and late-phase responses
90 [19]. NAM acts as an endogenous feedback inhibitor of SIRT activity and has been shown in
91 multiple systems to inhibit inﬂammatory pathways. For example, adequate NAD+[184_TD$DIFF] was required
92 for optimal [185_TD$DIFF]lipopolysaccharide (LPS)-induced tumor necrosis factor (TNF) production [186_TD$DIFF]and
93 NAM-inhibited SIRT activity to reduce, via translational control, the synthesis of this important
94 inﬂammatory cytokine [20]. Thus, [187_TD$DIFF]the acetylation status of metabolic enzymes, as well as levels
95 of metabolic intermediates that are generated by the protein deacetylase activity of classical
96 HDACs (acetyl-CoA) and SIRTs (NAM), control metabolic responses and inﬂammatory outputs
97 from macrophages.
98 The [188_TD$DIFF]Lysine Deacetylase Family
99 Classical HDACs
100 [189_TD$DIFF]Members of the classical HDAC family ( [190_TD$DIFF]classes I, II and IV), encompassing HDAC [191_TD$DIFF] –11, utilize
101 zinc as a cofactor in the catalytic site and are [192_TD$DIFF]subdivided based on the homology of their
102 deacetylase domains [21]. These enzymes developed [193_TD$DIFF]before the evolution of histones [194_TD$DIFF], and it
103 is now known that lysine deacetylation is a PTM that regulates many non-histone proteins.
104 Class I HDACs (1, 2, [195_TD$DIFF]3, and 8) are mostly restricted to the nuclear compartment and are
105 responsible for histone deacetylation and epigenetic control of gene expression. Class IIa
106 HDACs (4, 5, [196_TD$DIFF]7, and 9) share high homology in their C-terminal deacetylase [197_TD$DIFF]domains, and also
107 contain an N-terminal protein interaction region and nuclear export and import sequences.
108 These proteins shuttle between the nucleus and cytoplasm in response to a variety of cell
109 signals such as growth factors. Some reports have also demonstrated that members of this
110 subfamily can localize to other cellular compartments such as the mitochondria [22]. These
111 properties suggest that class IIa HDACs likely exert at least some effects by acting on non-
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112 histone substrates. HDAC6 and HDAC10, which comprise the class IIb subfamily, are
113 cytoplasmic enzymes that are distinguished by their duplicated deacetylase domains.
114 HDAC6 is known to deacetylate multiple cytosolic proteins such as tubulin, HSP [198_TD$DIFF] 0, and
115 peroxiredoxins. The sole class IV member, HDAC [199_TD$DIFF] 1, shares sequence similarity [200_TD$DIFF]with both
116 class I and II HDACs. Although it has not been as extensively studied as the other classical
117 HDACs, recent reports have demonstrated important functions for this enzyme in immune
118 cells, for example [201_TD$DIFF]in acting to constrain effector T cell function [23], to repress IL-10 in antigen
119 presenting cells [24], and to regulate [123_TD$DIFF]proinﬂammatory cytokines in neutrophils [25]. Small [202_TD$DIFF]-
120 molecule inhibitors of classical HDACs are approved clinically for oncological applications and
121 have shown therapeutic promise in experimental models of inﬂammatory diseases [21]. The
122 most widely studied of these are broad-spectrum inhibitors that target all or many of the
123 classical HDACs by binding to zinc within the catalytic site. More recently, class or isoform-
124 selective HDAC inhibitors have been developed by modiﬁcation of the moiety that interacts
125 with the rim region of the active site [26] or by taking advantage of residue differences in the
126 active [203_TD$DIFF]sites of class I and IIb versus IIa HDAC enzymes [27]. An in-depth understanding of how
127 HDACs regulate metabolic pathways in immune cells may provide insights into the molecular
128 basis for anti-inﬂammatory effects of broad-spectrum HDAC inhibitors, and should also help
129 [204_TD$DIFF]to guide the development of more speciﬁc inhibitors targeting individual HDACs for appli-
130 cations in inﬂammation-related diseases.
131 Sirtuins (SIRTs)
132 The [205_TD$DIFF]sirtuins, or class III HDACs, are highly conserved from bacteria to humans [28]. They
133 are NAD+ [171_TD$DIFF]-dependent protein deacetylases and/or mono-ADP-ribosyltransferases. Mam-
134 mals contain seven sirtuins (SIRT [206_TD$DIFF]1–7) that have high sequence homology across their
135 catalytic and NAD+ [207_TD$DIFF]-binding domains [29]. However, each member differs in subcellular
136 localization and catalytic activity (Table 1). SIRT1 and SIRT2 shuttle between the nucleus
137 and cytoplasm in a cell cycle- and cell-type dependent manner. SIRT [208_TD$DIFF]3–5 are mitochon-
138 drial sirtuins, while SIRT6 is found exclusively in the nucleus. SIRT7 is found in both the
139 nucleus and cytoplasm. Substrates of nuclear sirtuins include histones and non-histone
140 proteins such as nuclear transcription factors and cofactors, while cytoplasmic and
141 mitochondrial sirtuins play important roles in deacetylating key enzymes involved in
142 glycolysis, fatty acid oxidation (FAO), the TCA cycle [209_TD$DIFF], and other oxidative and metabolic
143 pathways [29]. [210_TD$DIFF]Because sirtuins are expressed throughout the body, they function as
144 cellular energy sensors and modulate a wide range of physiological and metabolic
145 processes. Dysregulation of their activity has been associated with various metabolic,
146 infectious [211_TD$DIFF], and neurological diseases, while their activation reportedly has beneﬁcial
147 effects in some preclinical rodent models [30], making them promising targets for phar-
148 macological intervention in human diseases.
149 HDACs as [212_TD$DIFF]Signaling Hubs in Regulating Immunometabolism
150 Given that the functions of some key metabolic enzymes are regulated by lysine acetylation
151 (below), and that metabolites generated through the actions of lysine deacetylases also control
152 immune processes, these enzymes are likely to be important in controlling cellular metabolism
153 and inﬂammatory responses. Numerous studies have linked speciﬁc classical HDACs [21] and
154 SIRTs [31] to inﬂammatory responses, but whether these effects relate to effects on metabolic
155 pathways has not yet been widely investigated. Below we describe studies across different
156 biological systems that implicate regulated lysine deacetylation in the control of aerobic
157 glycolysis and the pentose phosphate pathway, and describe how some of thesemodiﬁcations
158 may be involved in regulating inﬂammatory outputs from innate immune cells such as
159 macrophages.
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160 Lysine [213_TD$DIFF] eacetylases and the Control of Glycolysis
161 The Glycolysis Pathway
162 Although glycolysis is a relatively inefﬁcient means of generating ATP, heightened ﬂux
163 through this pathway in macrophages is essential for [214_TD$DIFF]the rapid generation of energy,
164 biosynthetic intermediates [215_TD$DIFF], and cofactors for enzymes, all of which are required for induc-
165 ible inﬂammatory responses. Lysine acetylation/deacetylation has a well-established role in
166 controlling metabolic enzymes in the TCA cycle, particularly through the actions of [216_TD$DIFF]sirtuins
167 (Box 2). Although somewhat less studied, this PTM has also been implicated in regulating
168 the stability and/or activity of some glycolytic enzymes (Figure 2). Below we describe known
169 roles for speciﬁc glycolytic enzymes in the control of innate immune functions and evidence
170 for regulated acetylation of these enzymes ( [217_TD$DIFF] able 2 and Figure 3), as well as gene regulatory
171 mechanisms by which classical HDACs and SIRTs inﬂuence glycolysis. Interestingly, the
172 pentose phosphate pathway is coupled to glycolysis and inducible effector functions of
173 macrophages, and enzymes in this pathway are also regulated by lysine deacetylases (Box
174 3 and Figure 2).
Table 1. Human[28_TD$DIFF]Q11 Sirtuins: Localization, Enzymatic Activity, and Roles in Glycolysis
Sirtuin [29_TD$DIFF]Location Main enzymatic activities Substrates involved in glycolysis and functions [30_TD$DIFF]Refs
SIRT1 Nucleus, [31_TD$DIFF]cytoplasm Deacetylation, ADP-ribosylation Activates PGC[32_TD$DIFF]-1a, which attenuates
transcription of glycolytic genes.
Regulates transcription of [33_TD$DIFF]the HIF1A gene by
deacetylating H3K14 and also deacetylates HIF[34_TD$DIFF]-
1a directly, leading to decreased glycolysis.
Inhibits glycolysis by deacetylating the glycolytic
enzyme PGAM-1
[35_TD$DIFF] 65,71,94]
SIRT2 Nucleus, [31_TD$DIFF]cytoplasm Deacetylation [36_TD$DIFF] eacetylates PEPCK that is required for
maintaining glucose homeostasis.
[37_TD$DIFF] eacetylates K305 of PKM2.
[38_TD$DIFF] eacetylates HIF-1a
[54,66,95]
SIRT3 Nucleus, [39_TD$DIFF]mitochondria Deacetylation Represses glycolysis by destabilizing HIF[40_TD$DIFF]-1a.
Overexpression of [41_TD$DIFF]SIRT3 increases glycolysis and
mitochondrial respiration.
Deacetylates K321 of PDH, leading to [42_TD$DIFF]activation
of the PDC
[62,67,96]
SIRT4 Mitochondria Deacetylation, ADP-ribosylation ADP-ribosylates glutamate dehydrogenase
(GDH), downregulating its activity and promoting
glutamine/glutamate metabolism and insulin
secretion.
Overexpression of [43_TD$DIFF]SIRT4 increases glycolysis and
mitochondrial respiration
[44_TD$DIFF] 96,97]
SIRT5 Mitochondria Demalonylation, [45_TD$DIFF]deacetylation Protein demalonylation by SIRT5 maintains
glycolysis, and malonylation of K184 of GAPDH
results in reduced glycolysis.
Overexpression of [46_TD$DIFF]SIRT5 increases glycolysis and
mitochondrial respiration
[44_TD$DIFF] 96,98]
SIRT6 Nucleus Deacetylation, ADP-ribosylation Deacetylates H3K9 at the promoter of the HIF1[47_TD$DIFF]A
gene, thereby repressing [48_TD$DIFF]HIF1A transcriptional
activity leading to diminished glycolysis under
homeostatic conditions.
Deacetylates K433 of dimeric PKM2
[49_TD$DIFF] 52,84]
SIRT7 Nucleus, [31_TD$DIFF]cytoplasm Deacetylation No current evidence for regulation of glycolysis
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175 Hexokinases (HKs)
176 The four isoforms of hexokinase (HK-I, HK-II, HK-III [218_TD$DIFF], and HK-IV, encoded by HK1, HK2, HK3 [17_TD$DIFF],
177 and GCK, respectively) vary in tissue expression and subcellular location [219_TD$DIFF], and also differ in
178 their afﬁnity towards glucose [32]. HK enzyme activity is inhibited by its enzymatic product,
179 glucose-6-phosphate, enabling tight regulation through feedback inhibition [33]. Thus, dys-
180 regulated expression and/or activity of HKs is a major contributor to [220_TD$DIFF]the increased glucose
181 gorging and elevated glycolysis that facilitate [221_TD$DIFF]cancer cell proliferation and metastasis [33,34].
182 HKs also have key functions in innate immunity. HK-I-dependent glycolysis was required for
183 activation of the NLRP3 inﬂammasome in LPS-primed mouse macrophages [35]. [222_TD$DIFF]By contrast,
184 HK-II plays a dominant role in TLR-inducible glycolysis in mouse dendritic cells [36], implying
185 that different HKs may control the glycolytic shift in different immune cell populations. This
186 study also showed that localization of HK-II to [223_TD$DIFF]mitochondria was important for the glycolytic
187 shift in DC. Intriguingly, another study showed that peptidoglycan activated the NLRP3
188 inﬂammasome through [224_TD$DIFF]N-acetylglucosamine-mediated inhibition of HK, resulting in its dis-
189 sociation frommitochondrial outer membranes [37]. Thus, it would appear that the [225_TD$DIFF]subcellular
190 localization of HKs dictate their immunological functions. Whether such functions are con-
191 trolled by lysine acetylation [226_TD$DIFF]remains be determined. However, a global acetylomics screen
192 identiﬁed HK-I and HK-II as acetylated proteins in human cell lines [38]. Furthermore, broad [227_TD$DIFF]-
193 spectrum classical HDAC inhibition in multiple myeloma cells decreased HK enzymatic
194 activity [16], suggesting that one or more of the classical HDACs may contribute to deace-
195 tylation-mediated activation of this [151_TD$DIFF]crucial step in the glycolytic pathway. These studies give
196 impetus to future investigations on regulated deacetylation of HK during macrophage
197 activation.
198 [228_TD$DIFF]Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH)
199 GAPDH catalyzes the conversion of glyceraldehyde-3-phosphate (G3P) to 1,3-bisphospho-D-
200 glycerate. This enzyme was originally thought to reside solely in the cytoplasm as a tetramer of
201 four identical 37 kDa subunits that perform its well-characterized glycolytic function [39].
202 However, based on its [229_TD$DIFF]oligomerization state, PTM, and subcellular [230_TD$DIFF]localization, GAPDH can
203 execute a multitude of other important cellular functions. Interestingly, in mammalian cancer
204 cells [231_TD$DIFF]GAPDH was recently predicted to be a key enzyme in regulating aerobic glycolysis [40].
205 That study proposed that the regulation of energy metabolism and cellular homeostasis by
206 GAPDH is much more complex than [232_TD$DIFF]was initially thought. Emerging evidence suggests that
207 [233_TD$DIFF]PTMs of GAPDH may control its subcellular [230_TD$DIFF]localization and functions, acting as a molecular
208 switch for both inducible glycolysis and [123_TD$DIFF]proinﬂammatory mediator production.
Box 2. Acetylation, the TCA Cycle [98_TD$DIFF], and Immunometabolism
In the mitochondria, eight enzymatic reactions in the TCA cycle [99_TD$DIFF]utilize pyruvate-derived acetyl-CoA to transfer electrons
to NAD or FAD, generating two ATP, six NADH molecules[100_TD$DIFF], and two FADH2 per glucose molecule for use by the [101_TD$DIFF]ETC.
Every TCA enzyme can be acetylated [85] [102_TD$DIFF]and, similarly to glycolytic enzymes, distinct changes in TCA cycle enzyme
expression and/or function are crucial for [103_TD$DIFF]the accumulation of metabolic intermediates such as succinate, itaconate,
malate[104_TD$DIFF], and fumarate that act as [105_TD$DIFF]signaling molecules to regulate macrophage immunometabolism. For example, citrate
exported from the mitochondria can be converted into cytosolic acetyl-CoA and used for histone acetylation and [106_TD$DIFF]the
expression of glycolytic genes [76]. Citrate can also be converted to itaconate, which inhibits succinate dehydrogenase
(SDH) to promote accumulation of succinate [8]. This provides a mechanism to promote [107_TD$DIFF]proinﬂammatory (e.g., IL-1b)
and reduce anti-inﬂammatory (e[108_TD$DIFF].g., IL-10) gene expression [9,86], as well as [109_TD$DIFF]to amplify ROS production [86]. SDH has
dual functions [110_TD$DIFF]: within the TCA cycle it [111_TD$DIFF]oxidizes succinate to fumarate but also operates as [112_TD$DIFF]complex II of the ETC.
Acetylation of SDH at the active site interferes with substrate binding and decreases enzymatic activity [87], whereas
deacetylation by [113_TD$DIFF]mitochondrial SIRT3 increases SDH enzymatic activity [87,88]. Other mitochondrial enzymes that can
be targeted by SIRT3 include acetyl-CoA synthetase 2, isocitrate dehydrogenase[114_TD$DIFF], and glutamate dehydrogenase.
Thus, regulated acetylation provides ameans of controlling the activity of SDH and other mitochondrial enzymes, and[115_TD$DIFF], in
turn, immunometabolism.
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(Figure legend continued on the bottom of the next page.)
[10_TD$DIFF]Acetylation Regulates Glycolytic Enzyme Form and Function. (A) Examples of glycolyticQ9 enzymes
regulated by acetylation, as well as the speciﬁc acetyltransferases/deacetylases implicated in these processes. Hex-
okinase (HK), a rate-limiting enzyme in the glycolysis pathway, phosphorylates glucose to generate glucose-6-phosphate
(G6P). This enzyme is known to be lysine-acetylated [38], and [11_TD$DIFF]histone deacetylase inhibition (HDACi) reduced the activity of
this enzyme [12_TD$DIFF] 16], implicating HK deacetylation in inducible glycolysis in activated macrophages. Multiple lysine residues of
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209 In macrophages, binding of GAPDH to the [234_TD$DIFF] 0-untranslated region (UTR) of TNFmRNA couples
210 expression of this key inﬂammatory cytokine with the cellular metabolic state. When glycolytic
211 rate is low, binding of GAPDH represses TNF expression through post-transcriptional mecha-
212 nisms. Enhanced glycolysis dissociates the complex, presumably by increasing the amount of
213 GAPDH substrate (G3P) to compete at the enzymatic site, simultaneously enabling inducible
214 TNF expression and regulated immunometabolism [41,42]. A similar mechanism occurs in T
215 cells, where GAPDH directly binds to mRNA encoding IFN[235_TD$DIFF]-g and prevents its translation [43].
216 When T cells are activated, increased glucose inﬂux promotes the disassociation of GAPDH
217 from IFN [236_TD$DIFF]-g mRNA, allowing translation and secretion of this effector cytokine, as well as
218 ampliﬁed aerobic glycolysis that is required for T cell proliferation [43]. Intriguingly, another study
219 showed that GAPDH was recruited to the plasma membrane in activated macrophages. [237_TD$DIFF]At the
220 membrane it functioned as an immune receptor for plasminogen, controlling the recruitment of
221 macrophages to sites of inﬂammation [44]. Collectively, these studies suggest that the cellular
222 metabolic state and subcellular localization of GAPDH dictates its role in regulating
223 immunometabolism.
224 Emerging evidence suggests that regulated lysine acetylation of GAPDH may be an important
225 switch that controls its dual metabolic and immune regulatory functions. For example, in
226 response to systemic bacterial infection, [238_TD$DIFF]acetylation of GAPDH on lysine (K) 217 in mouse
227 memory CD8+ T cells supported GAPDH enzymatic activity. The enhanced glycolytic rate was
228 required for optimal memory recall responses to Listeria monocytogenes [45]. In cancer cells,
229 high glucose levels promoted the acetylation of GAPDH at K254, enhancing its enzymatic
230 activity to support proliferation [46]. This inducible acetylation was mediated by the acetyl-
231 transferase PCAF, whereas glucose deprivation promoted an interaction with HDAC5, its
232 deacetylation, and a reduction in GAPDH enzymatic activity [46]. Acetylation at other residues
233 (K117, [240_TD$DIFF] 27, and 251) was also required for GAPDH nuclear translocation under apoptotic
234 stress in NIH3T3 cells [47]. Whether the regulation of GAPDH acetylation by glucose availability
235 in macrophages alters its subcellular localization and/or interaction with cytokine mRNAs is
236 unknown at this stage. Nonetheless, the effects of stimuli that control immunometabolism in
237 macrophages, such as TLR ligands, on GAPDH acetylation/deacetylation warrant further
238 investigation.
239 The [241_TD$DIFF]Pyruvate Kinase M Isoform PKM2
240 The various non-glycolytic functions of PKM2 in inﬂammatory cells position it as a hallmark
241 enzyme that bridges metabolism and immunity. In the glycolytic pathway, tetrameric PKM2
242 [89_TD$DIFF]catalyzes the rate-limiting ﬁnal step of glycolysis by transferring the phosphate group of
243 phosphoenolpyruvate to ADP, producing pyruvate and ATP. This tetrameric form relies on
244 the availability of the upstream intermediate fructose-1,6-bisphosphate (F-1,6-BP), and
GAPDH can be acetylated [13_TD$DIFF](ac). PCAF-mediated acetylation of GAPDH on K117/227/251 was required for nuclear
translocation and subsequent moonlighting functions in gene regulation. Acetylation of [14_TD$DIFF]lysine (K) 217 [45] and K254 [46]
enhanced the glycolytic enzymatic activity of GAPDH[15_TD$DIFF], whereas deacetylation by HDAC5 reduced it [46]. Acetylation of
lysine residues on PKM2 can regulate its functions in multiple ways. PCAF-mediated acetylation of K305 promotes [16_TD$DIFF]its
association with chaperone HSC70, targeting PKM2 for lysosomal degradation [53][17_TD$DIFF], and SIRT2 can deacetylate this
residue to promote tetramer formation [54]. PCAF-mediated acetylation on K433 of the cytosolic, tetrameric form of PKM2
interferes with FBP binding and promotes PKM2 dimer formation [51]. Nuclear SIRT6 can deacetylate dimeric PKM2,
enhancing its nuclear export [52]. ([18_TD$DIFF]B) Key enzymes in the pentose phosphate pathway (PPP) [19_TD$DIFF]are regulated by acetylation.
Acetylation of K403 on G6PD inhibited enzymatic activity, whereas deacetylation by SIRT2 enhanced its activity [91].
6PGD can be regulated by acetylation at two sites; K76 acetylation promotes NADP+ [20_TD$DIFF] binding and K294 acetylation
promotes active dimer formation. HDAC4 can deacetylate both of theseQ10 residues [93]. [21_TD$DIFF]Abbreviations: G6P, glucose-6-
phosphate; 6PGL, 6-phosphogluconolactone; 6PG, 6-phosphogluconate; Ru5P, ribulose-5-phosphate.
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[50_TD$DIFF] able 2. Identiﬁcation of [51_TD$DIFF]Lysine Residues in Glycolytic Enzymes Regulated by Acetylation
[52_TD$DIFF]Enzyme Acetyl-lysine residue(s) [53_TD$DIFF] unctional consequence of lysine acetylation/
deacetylation
[54_TD$DIFF]Refs
Hexokinase (HK)
[55_TD$DIFF]Hexokinase domain-containing 1 K173a, K174a Currently unknown, residues identiﬁed by global
proteomic screening
[85]
HK-I K453a [57_TD$DIFF][56_TD$DIFF] Currently unknown, residues identiﬁed by global
proteomic screening
[56_TD$DIFF] 38]
HK-II K337a [58_TD$DIFF], K346a
Phosphofructokinase-1 (PFK1)
6-Phosphofructokinase type C K797a [57_TD$DIFF][59_TD$DIFF] Currently unknown, residues identiﬁed by global
proteomic screening
[60_TD$DIFF] 85]
Phosphofructokinase, muscle K113a [61_TD$DIFF]
Phosphofructokinase, platelet K776a [62_TD$DIFF]
6-Phosphofructokinase, liver type K762a [63_TD$DIFF]
Aldolase K12, K41, K146 Acetylation of K146 [64_TD$DIFF]is predicted to decrease
enzyme activity
[65_TD$DIFF] 99]
Triosephosphate isomerase (TPI) K222a [57_TD$DIFF] Currently unknown, residues identiﬁed by global
proteomic screening
[56_TD$DIFF] 99]
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) K117, K227, K251, K254 Acetylation of K117, K227, [66_TD$DIFF]and K251 is required
for nuclear translocation of GAPDH. HDAC5-
mediated deacetylation of K254 decreases
enzyme activity
[65_TD$DIFF] 46,47]
Phosphoglycerate kinase-1 (PGK1) K388 ARD1-mediated K388 acetylation of PGK1
increases kinase activity to phosphorylate Beclin1
S30 and promote autophagy initiation and
tumorigenesis
[67_TD$DIFF] 100]
Phosphoglycerate mutase (PGAM)
[68_TD$DIFF]PGAM1 K251, K253, K254 [69_TD$DIFF]Acetylation enhances enzyme activity. SIRT1-
mediated deacetylation decreases enzyme
activity
[70_TD$DIFF] 94]
PGAM2 K100 [71_TD$DIFF]Acetylation decreases enzyme activity. SIRT2-
mediated deacetylation increases enzyme activity
[70_TD$DIFF] 101]
PGAM1/2 K100, K106, K113, K138 [72_TD$DIFF]SIRT2-mediated deacetylation decreases
enzyme activity
[70_TD$DIFF] 102]
Enolase K71a [73_TD$DIFF] Currently unknown, residues identiﬁed by global
proteomic screening
[74_TD$DIFF] 99]
Pyruvate kinase M2 (PKM2) K305, K433 [75_TD$DIFF]K305 acetylation decreases enzyme activity and
increases lysosomal degradation.
K433 acetylation prevents activation and
promotes nuclear accumulation and kinase
activity
[70_TD$DIFF] 51,53]
Pyruvate dehydrogenase (PDHA1) K321 [72_TD$DIFF]SIRT3-mediated deacetylation increases PDHA1
enzyme activity and attenuates the Warburg
effect
[76_TD$DIFF] 62]
Lactate dehydrogenase A (LDHA) K5 [77_TD$DIFF]Acetylation decreases enzyme activity. SIRT2-
mediated deacetylation increases enzyme
activity.
LDHA acetylation decreases cell proliferation and
migration. SIRT3-mediated deacetylation
increases enzyme activity
[78_TD$DIFF] 103,104]
aLysine residues identiﬁed using global proteomic screening in the indicated reference[79_TD$DIFF]; peptide sequences werematched to reference sequences to [80_TD$DIFF]identify the speciﬁc
lysine residue(s) indicated here.
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245 dissociation of the tetramer to a dimeric form occurs when concentrations of this intermediate
246 are low [48] or when phosphorylation of Y105 disrupts binding of F-1,6-BP [48]. The reduced
247 enzymatic activity of dimeric PKM2 allows build-up of key glycolytic intermediates to be used as
248 precursors for protein, lipid [242_TD$DIFF], and nucleic acid synthesis. Extracellular signals such as growth
249 factors and inﬂammatory stimuli can also [243_TD$DIFF]induce the formation of dimeric PKM2, which
250 reportedly has functions that are independent of its role as a glycolytic enzyme, including
251 as a nuclear protein kinase and a [167_TD$DIFF]coactivator of transcription factors [11]. For example, TLR4
252 [105_TD$DIFF]signaling in macrophages induced association of PKM2 with HIF-1a in the nucleus to drive
253 expression of glycolytic (e[244_TD$DIFF].g., Ldha) and inﬂammatory genes (e[245_TD$DIFF].g., Il1b) [11]. In addition, in
254 macrophages from patients with coronary artery disease, nuclear translocation of dimeric
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Figure 3. [23_TD$DIFF][24_TD$DIFF][26_TD$DIFF] eacetylases as Potential
Links Between Regulated Metabo-
lism and Inﬂammatory Outputs of
Macrophages. Individual HDACs and
SIRTs have both pro- and anti-inﬂamma-
tory functions in macrophages. In the
context of the former, these lysine dea-
cetylases positively regulate the function
or expression of key enzymes in the gly-
colysis pathway (e.g., HK, PKM2) and the
PPP (e.g., G6PD), as well as speciﬁc func-
tional responses of macrophages (e.g.,
proinﬂammatory cytokine production,
antimicrobial responses). Thus, deacety-
lases are strong candidates as molecular
links between regulated metabolism and
biological responses of macrophages
(teal arrows). In addition, HDACs and
SIRTs are also likely to regulate some
macrophage functions in host defense
and inﬂammation independently of meta-
bolic control (orange arrow). Abbrevia-
tions: HDAC, histone deacetylase; PPP,
pentose phosphate pathway; ROS, reac-
tive oxygen species; SIRT, sirtuin.
Box 3. Control of the [116_TD$DIFF]Pentose Phosphate Pathway (PPP) by Lysine Acetylation
[117_TD$DIFF] he PPP utilizes glycolysis-derived glucose-6-phosphate (G6P) to generate reducing equivalents in the form of NADPH
and ribose-5-phosphate for nucleotide synthesis. In TLR-activated macrophages, ﬂux through the PPP is enhanced to
provide NADPH for the oxidative [118_TD$DIFF]respiratory burst and to generate glutathione as a buffer for ROS. Glucose-6-
phosphate dehydrogenase (G6PD), the ﬁrst and rate-limiting enzyme in the PPP, has been extensively implicated
in inﬂammatory responses and is regulated by acetylation. G6PD [89_TD$DIFF]catalyzes the oxidation of G6P into 6-phosphoglu-
cono-d-lactone, with concomitant reduction of NADP+[119_TD$DIFF] to NADPH. Active G6PD exists as a dimer of two identical
monomers, with each monomer containing a G6P-binding site and a catalytic coenzyme site [120_TD$DIFF]that binds NADP+. LPS
and free fatty acids stimulate G6PD expression in macrophages, and its expression is elevated in adipose tissue
macrophages from obese patients. The elevated expression of this enzyme promoted oxidative stress and activated the
p38MAPK and NF [122_TD$DIFF]-kB signaling pathways to drive expression of [123_TD$DIFF]proinﬂammatory cytokines [89]. Conversely, deletion of
G6PD attenuated macrophage inﬂammatory responses, improved insulin sensitivity [124_TD$DIFF], and reduced chronic tissue
inﬂammation in a model of diet-induced obesity [90]. Targeting aberrant expression and/or activity of G6PD would
thus be predicted to reduce inﬂammation-associated pathology. Proteomic acetylome proﬁling has identiﬁed seven
lysine residues on G6PD that can be acetylated (K89, K171, K386, K403, K432, K [125_TD$DIFF]497, and K514), and subsequent
studies have identiﬁed a regulatory role [126_TD$DIFF]for K403 acetylation. In HEK293 cells, active dimer formation was prevented by
K403 acetylation, thereby reducing G6PD enzymatic activity [91]. Conversely [127_TD$DIFF], deacetylation of this residue by SIRT2
activated enzyme activity and enhanced NADPH production [91,92]. Given the importance of the respiratory burst for
antimicrobial responses, a detailed understanding of how acetylation regulates PPP enzyme activity in macrophages
may have implications for host-directed antimicrobial therapies.
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255 PKM2 facilitated binding with STAT3 to [246_TD$DIFF]promote the expression of IL-1b and IL-6 [12]. Despite
256 such evidence (and that described below), the protein kinase activity of PKM2 remains
257 somewhat controversial; for example, Hosios [247_TD$DIFF]et al. [49] could ﬁnd no evidence of direct transfer
258 of phosphate from ATP to protein by PKM2. Interestingly, dimeric PKM2 was also detected in
259 the circulation of cancer patients, and was shown to promote angiogenesis [50]. The contri-
260 butions of extracellular PKM2 to inﬂammation are not well understood at this stage, and indeed
261 [248_TD$DIFF]there is still much to uncover about the speciﬁc molecular mechanisms by which intracellular
262 PKM2 drives macrophage inﬂammatory responses.
263 Several lysine residues in PKM family members can be regulated by acetylation. K433 is located
264 in PKM2-speciﬁc exon 10 and has been linked to the switch between its cytoplasmicmetabolite
265 kinase activity and nuclear protein kinase function. Acetylation of this residue by the HAT p300
266 interfered with the ability of F-1,6-BP to bind [249_TD$DIFF]to PKM2, driving the switch to a dimer and
267 promoting nuclear accumulation and its protein kinase activity [51]. In cancer cells, this
268 promoted cell proliferation and tumorigenesis, and [250_TD$DIFF]cotreatment with a pan inhibitor of classical
269 HDACs (trichostatin A) and NAM enhanced this modiﬁcation, implicating both HDACs and
270 SIRTs in its regulation. Additional studies in cancer cells showed that [251_TD$DIFF]nucleus-localized SIRT6
271 can deacetylate K433 of dimeric PKM2 to promote nuclear export and loss of its protein kinase
272 activity [52]. Also in cancer cells, PCAF-mediated acetylation of K305 in response to high
273 glucose decreased classical pyruvate kinase activity, enhanced [103_TD$DIFF]the accumulation of glycolytic
274 intermediates [252_TD$DIFF], and promoted autophagy-mediated degradation of PKM2 [53]. SIRT2 deace-
275 tylated this residue to promote tetrameric pyruvate kinase activity [54], and treatment with
276 trichostatin A plus NAM decreased PKM2 protein expression [53], indicating that deacetylation
277 of this residue is able to [253_TD$DIFF]stabilize the protein. Finally, in breast cancer cells, another pan classical
278 HDAC inhibitor, SAHA, induced acetylation of K305 [55]. No functional outcome of this was
279 described [254_TD$DIFF], and a clear delineation of how classical HDACs and SIRTs regulate PKM2 acetyla-
280 tion in speciﬁc cell types is still required. Residues of PKM2 regulated by acetylation are yet to
281 be identiﬁed in immune cells [255_TD$DIFF]; however, a recent study in macrophages demonstrated that
282 succinylation of K311 promoted formation of the nuclear dimer, enabling association with HIF-
283 1a and inducible IL-1b expression [56]. SIRT5 was shown to be required for desuccinylation of
284 this residue, inducing the tetrameric form and preventing inﬂammatory mediator production. In
285 keeping with this regulatory role, [256_TD$DIFF]Sirt!/![239_TD$DIFF] mice were highly susceptible to DSS-induced colitis
286 [56]. Lysine succinylation frequently overlaps with acetylation [57][17_TD$DIFF], and this opens up the
287 interesting possibility of crosstalk between different lysine modiﬁcations (e.g[23_TD$DIFF]., acetylation,
288 succinylation) on K311 or other lysine residues of PKM2 to control its stability and/or function.
289 In this regard, HDACs/SIRTs may act as gatekeepers, deacetylating lysine residues to enable
290 alternative PTMs.
291 Pyruvate [257_TD$DIFF] ehydrogenase (PDH)
292 The pyruvate dehydrogenase complex (PDC) is formed by the association of three catalytic
293 enzymes; [258_TD$DIFF]PDH (E1), dihydrolipoamide transacetylase (E [259_TD$DIFF] ), and dihydrolipoamide dehydroge-
294 nase (E3), as well as the E3-binding protein that tethers them together [58]. When [260_TD$DIFF]localized in
295 the mitochondrial membrane, the PDC decarboxylates pyruvate into acetyl-CoA for use by the
296 TCA cycle, linking glycolysis to the TCA cycle and determining whether pyruvate is used for
297 OXPHOS or is reduced to lactate to sustain aerobic glycolysis. Intriguingly, despite its large size,
298 intact and functional PDC can translocate across the mitochondrial membrane and shuttle to
299 the nucleus, where it provides a [261_TD$DIFF]localized nuclear pool of acetyl-CoA for histone acetylation and
300 [262_TD$DIFF]the control of gene expression [59]. [263_TD$DIFF]Because PDH catalyzes the rate-limiting step of pyruvate
301 decarboxylation, the activity of this subunit determines the rate of ﬂux, which in turn replenishes
302 the TCA cycle. [264_TD$DIFF]Proinﬂammatorymacrophages sustain pyruvate oxidation through PDH and use
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303 it to generate citrate in themitochondria, providing substrate for the production of itaconate and
304 for lipogenesis [60]. The major inhibitory control point of PDC activity is phosphorylation on
305 three serine residues of PDH by pyruvate dehydrogenase kinase (PDK) [61]. SIRT3-mediated
306 deacetylation of PDH at K321 increased its enzymatic activity in cancer cells [62][17_TD$DIFF], and
307 acetylation at this residue inhibited activity by recruiting PDK [63]. Thus, it would appear that
308 deacetylation of PDH provides a means [265_TD$DIFF]to activate the PDC. There is other evidence of indirect
309 control of PDH activity via regulated lysine acetylation in cancer cells. Acetylation of K202 of
310 pyruvate dehydrogenase phosphatase 1 (PDP1) inhibits its interaction with PDH, preventing
311 dephosphorylation-mediated activation of PDH [63]. Thus, deacetylation of PDP1 would be
312 predicted to [266_TD$DIFF]favor PDH activation. ACAT1 and SIRT3 were identiﬁed as the responsible lysine
313 acetylase and deacetylase, respectively, in this pathway.
314 HDAC/SIRT-[267_TD$DIFF]Mediated Control of Glycolysis Through Gene Regulation
315 In addition to acetylation/deacetylation-mediated control of the activity of glycolytic enzymes,
316 HDACs and SIRTs can also inﬂuence glycolysis by modulating the expression of glycolysis-
317 associated genes, either by deacetylating transcription factors or histones (epigenetic mecha-
318 nisms). For example, HIF-1a, a key transcription factor at the convergence of inﬂammatory and
319 metabolic signals, regulates [106_TD$DIFF]the expression of glycolytic genes such as glucose transporters
320 (Glut1), Hk2, Pkm[17_TD$DIFF], and Ldha, thereby enhancing glycolytic ﬂux [64]. HIF-1a is known to be
321 regulated by acetylation; SIRT1 [65] and SIRT2 [66] can each directly bind to, deacetylate [268_TD$DIFF], and
322 inactivate HIF-1a, while SIRT3-dependent reactive oxygen species (ROS) production [163_TD$DIFF]stabilizes
323 HIF-1a by targeting the prolyl hydroxylases that induce degradation [67]. Class I and II classical
324 HDACs can also regulate HIF-1a [269_TD$DIFF]localization, stability, and function to control glycolytic and
325 inﬂammatory gene expression. Furthermore, [187_TD$DIFF]the enzymatic activity of classical HDACs was
326 required for HIF-1a-dependent transcriptional responses in TLR-activated macrophages [68].
327 The peroxisome proliferator-activated receptor [270_TD$DIFF]g coactivator 1a (PGC-1a) and Forkhead [271_TD$DIFF]box O
328 (FoxO) transcription factors are other deacetylase-modulated targets that control glycolytic
329 gene expression and regulate TLR4 [105_TD$DIFF]signaling inmacrophages [69,70]. In hepatocytes, PGC-1a
330 is deacetylated by SIRT1 to modulate the balance of glycolytic and gluconeogenic genes [71].
331 Also in the liver, class IIa HDACs are [272_TD$DIFF]necessary to recruit HDAC3 for deacetylation and [273_TD$DIFF]the
332 activation of FoxO transcription factors, thus enabling [274_TD$DIFF]the expression of enzymes involved in
333 gluconeogenesis [72]. In adipocytes, [275_TD$DIFF]sirtuins can also directly deacetylate FoxO transcription
334 factors to regulate cell metabolism; SIRT1-mediated deacetylation of FoxO1 resulted in
335 increased adiponectin transcription [73], which in turn modulated glucose metabolism, FAO[276_TD$DIFF],
336 and insulin levels. Whether these speciﬁc HDACs also deacetylate PGC-1a and/or FoxO to
337 control regulated metabolism in macrophages remains an open question.
338 Numerous studies have demonstrated that metabolic input is integrated into changes at the
339 level of chromatin structure. Lactate, the end[277_TD$DIFF]-product of aerobic glycolysis, inhibits HDAC
340 activity [74], thus providing [278_TD$DIFF]a molecular mechanism by which the metabolic state of the cell can
341 exert epigenetic control. In keeping with this, glycolytic metabolism promoted global histone
342 acetylation and an open chromatin conﬁguration in cancer cells [75], likely by providing
343 additional acetyl-CoA for HATs [76,77] and by increased production of HDAC-inhibitory lactate
344 [74]. Furthermore, extracellular signals that inﬂuence macrophage activation status can regu-
345 late gene expression through control of metabolites. For example, IL-4 [105_TD$DIFF]signaling induced a
346 nuclear pool of acetyl-CoA that was necessary for histone acetylation and [279_TD$DIFF]the expression of
347 genes associated with alternatively activated macrophages [78]. In addition, epigenetic reprog-
348 ramming of monocytes in response to Candida albicans required high glucose consumption
349 coupled with elevated lactate production and a high NAD+[179_TD$DIFF]/NADH ratio [79], with SIRT[280_TD$DIFF]1 and 6
350 being implicated in this process [19,79]. With respect to speciﬁc epigenetic mechanisms,
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351 SIRT1 directly regulates transcription via deacetylation of histones such as H1 [80], H3 [80,81] [17_TD$DIFF],
352 and H4 [80]. By deacetylating H3K14 [281_TD$DIFF]at the promoter of the HIF[282_TD$DIFF]1A gene, SIRT1 inhibited HIF-
353 1a expression [82]. Similarly, in activated skeletal muscle stem cells, increased glycolysis was
354 associated with reduced SIRT1-mediated deacetylation of H4K16 [83]. SIRT6 also regulates
355 glucose homeostasis by deacetylation of H3K9 to inhibit the expression of various HIF-1a-
356 dependent glycolytic genes [19,84]. Thus, multiple SIRT family members appear to be particu-
357 larly important for [283_TD$DIFF]the epigenetic control of glycolysis [284_TD$DIFF]in several cellular systems.
358 Concluding [285_TD$DIFF]Remarks
359 There is very strong evidence [286_TD$DIFF]that speciﬁc HDAC/SIRT enzymes [287_TD$DIFF]deacetylate metabolic
360 enzymes and [288_TD$DIFF]regulate metabolic pathways in cancer cells. While aerobic glycolysis is
361 [289_TD$DIFF]utilized by both cancer cells and activated macrophages, there are many questions that remain
362 about how HDACs and SIRTs control macrophage immunometabolism ( [290_TD$DIFF]Outstanding Ques-
363 tions). For example, there are likely to be many differences in the expression and/or [230_TD$DIFF]localization
364 of individual lysine deacetylases between cancer cell lines and primary immune cells. Thus,
365 detailed mechanistic studies [291_TD$DIFF]will now be necessary to better understand the roles of individual
366 HDAC/SIRT enzymes in regulating glycolysis in macrophages. Some of these enzymes have
367 already been linked to the regulation of macrophage inﬂammatory responses, for example
368 HDAC7 that promotes macrophage-mediated inﬂammatory responses [68] and SIRT5 that
369 plays a regulatory role by constraining the inﬂammatory functions of PKM2 [56]. A more
370 comprehensive molecular understanding of how speciﬁc lysine deacetylases control speciﬁc
371 glycolytic enzymes in resting and activated macrophages is likely to deliver new opportunities
372 for manipulating immunometabolism in these cells as an anti-inﬂammatory strategy for man-
373 aging disease.
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